Bright Minds Biosciences (DRUG) Other Non-Current Liabilities (2022 - 2024)
Bright Minds Biosciences' (DRUG) quarterly Other Non-Current Liabilities came in at $333959.3 in Q3 2024, down 46.18% YoY from $620490.3 in Q4 2023, and down 45.09% on a QoQ basis from $608187.6 in Q2 2024.
Bright Minds Biosciences (DRUG) Other Non-Current Liabilities (2022 - 2024) Analysis & Trends
Bright Minds Biosciences (DRUG) has 3 years of Other Non-Current Liabilities data on file, last reported at $333959.3 in Q3 2024.
- Quarterly Other Non-Current Liabilities fell 46.18% year-over-year to $333959.3 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $333959.3 (down 46.18% YoY) and the FY2024 annual result came in at $333959.3, down 46.18% from the prior year.
- Other Non-Current Liabilities eased to $333959.3 in Q3 2024, from $608187.6 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $620490.3 in Q3 2023 to a low of $9412.1 in Q2 2022.
- A 3-year average of $516417.3 and a median of $612814.6 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 6479.42% — and 2024, when it plunged 46.18%.
- Tracing DRUG's Other Non-Current Liabilities over 3 years: stood at $612814.6 in 2022, then declined by 0.29% to $611011.6 in 2023, then tumbled by 45.34% to $333959.3 in 2024.
- The last three Other Non-Current Liabilities figures came in at $333959.3 (Q3 2024), $608187.6 (Q2 2024), and $617315.0 (Q1 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 333,959.34 |
| Jun 30, 2024 | 608,187.57 |
| Mar 31, 2024 | 617,315.00 |
| Dec 31, 2023 | 611,011.63 |
| Sep 30, 2023 | 620,490.33 |
| Jun 30, 2023 | 619,260.87 |
| Mar 31, 2023 | 615,304.59 |
| Dec 31, 2022 | 612,814.55 |
| Jun 30, 2022 | 9,412.09 |